Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-03
2010-10-26
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07820684
ABSTRACT:
The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.
REFERENCES:
patent: WO 2005/037825 (2005-04-01), None
patent: WO 2005/037825 (2005-04-01), None
Berge, et al., Pharmaceutical Salts, J. of Pharm. Sciences (1977).
Advani, “FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications,” Current Pharmaceutical Design 11(26): 3449-3457, 2005.
Alexis et al., “An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients,” Melanoma Research 15(4): 283-285, 2005.
Alvarez et al., “Biology of Platelet-Derived Growth Factor and Its Involvement in Disease,” Mayo Clinic Proc 81(9): 1241-1257, Sep. 2006.
Blume-Jensen et al., “Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis,” The EMBO Journal 10(13): 4121-4128, 1991.
Corbin et al., “In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit,” Blood 106(1): 227-234, Jul. 1, 2005.
Corless et al., “PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib,” J Clin Oncol 23(23):5357-5364, Aug. 10, 2005.
Daboussi et al., “DNA double-strand break repair signalling: The case of RAD51 post-translational regulation,” Cellular signalling 14: 969-975, 2002.
De Giorgi and Verweij, “Imatinib and gastrointestinal stromal tumors: Where do we go from here?”, Mol Cancer Ther 4(3): 495-501, Mar. 2005.
Foster et al., “Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase,” Journal of Molecular Graphics and Modelling 23: 139-152, 2004.
Frost et al., “Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant,” Molecular Cancer Therapeutics 1: 1115-1124, Oct. 2002.
Gotlib et al., “Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V Kit mutation,” Blood 106(8): 2865-2870, Oct. 15, 2005.
Growney et al., “Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412,” Blood 106(2): 721-724, Jul. 15, 2005.
Hansen et al., “The Role of RAD51 in Etoposide (VP16) Resistance in Small Cell Lung Cancer,” Int J Cancer 105: 472-479, 2003.
Heinrich et al., “Biology and Genetic Aspects of Gastrointestinal Stromal Tumors: KIT Activation and Cytogenetic Alterations,” Human Pathology 33(5): 484-495, May 2002.
Heinrich et al., “Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies,” J Clin Oncol 20(6): 1692-1703, Mar. 15, 2002.
Henning and Stürzbecher, “Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance,” Toxicology 193: 91-109, 2003.
Hirota et al., “Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors,” Science 279: 577-580, Jan. 23, 1998.
Juurikivi et al., “Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis,” Ann Rheum Dis 64: 1126-1131, 2005.
Qiao et al., “High-level expression of Rad51 is an independent prosnostic marker of survival in non-small-cell lung cancer patients,” British Journal of Cancer 93(1): 137-143, 2005.
Schmidt-Arras et al., “Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia,” Current Pharmaceutical Design 10(16): 1867-1883, 2004.
Tian et al., “Activating c-kit Gene Mutations in Human Germ Cell Tumors,” Am J Pathol 154(6): 1643-1647, Jun. 1999.
Yarden et al., “Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand,” The EMBO Journal 6(11): 3341-3351, 1987.
Bearss David J.
Joshi-Hangal Rajashree
Liu Xiao-Hui
Phiasivongsa Pasit
Redkar Sanjeev G.
Leeser Erich A
Seed IP Law Group PLLC
SuperGen, Inc.
Wilson James O
LandOfFree
Pharmaceutical formulations comprising salts of a protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations comprising salts of a protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations comprising salts of a protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4153094